Tg Therapeutics Stock Filter Stocks by Fundamentals
| TGTX Stock | USD 40.21 0.58 1.42% |
TG Therapeutics fundamentals help investors to digest information that contributes to TG Therapeutics' financial success or failures. It also enables traders to predict the movement of TGTX Stock. The fundamental analysis module provides a way to measure TG Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TG Therapeutics stock.
TGTX | Shares Owned by Institutions |
TG Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of TG Therapeutics from analyzing TG Therapeutics' financial statements. These drivers represent accounts that assess TG Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TG Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 980.9M | 6.0B | 1.6B | 2.4B | 4.4B | 4.6B | |
| Enterprise Value | 909.1M | 5.5B | 1.6B | 2.4B | 4.4B | 4.7B |
TG Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, TG Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to TG Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
TG Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in TG Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of TG Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing TG Therapeutics' value.| Shares | Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Hood River Capital Management Llc | 2024-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 1 M | Amvescap Plc. | 2024-12-31 | 929.7 K | Bank Of New York Mellon Corp | 2024-12-31 | 923.5 K | Principal Financial Group Inc | 2024-12-31 | 830.2 K | Susquehanna International Group, Llp | 2024-12-31 | 827.1 K | Blackrock Inc | 2024-12-31 | 21.9 M | Vanguard Group Inc | 2024-12-31 | 15.6 M |
TGTX Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0578 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 6.35 B | ||||
| Shares Outstanding | 157.07 M | ||||
| Shares Owned By Insiders | 9.37 % | ||||
| Shares Owned By Institutions | 62.81 % | ||||
| Number Of Shares Shorted | 25.74 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 28.81 X | ||||
| Price To Sales | 20.43 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 290.52 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 253.72 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Short Ratio | 7.84 X | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 42.83 | ||||
| Number Of Employees | 338 | ||||
| Beta | 2.3 | ||||
| Market Capitalization | 6.72 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
| Net Asset | 577.69 M |
About TG Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.